Plain-English translation of NCT06718205 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing combined with and chemotherapy as a first-line treatment for advanced esophageal squamous cell carcinoma. Researchers want to see if this three-drug combination can help people whose cancer has returned or spread after previous surgery or radiation therapy. The study will track how well the medication works and how safe it is over time.
Esophageal cancer that comes back or spreads is very difficult to treat, and current options are limited. This trial is exploring whether combining three different types of medications—each working in different ways—might be more effective at fighting this aggressive cancer than existing treatments.
You likely qualify if…
You likely don't qualify if…
You would receive 4 to 6 cycles of the three-drug combination as initial treatment, with each cycle typically lasting about 2–3 weeks. After that, you would continue taking the medication as maintenance therapy until your cancer progresses, you experience unmanageable side effects, or up to 2 years total—whichever comes first. You would have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how the treatment is working and to check for any side effects. After you stop the medication, you would be followed for an additional year to track your long-term health.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Zhengzhou University
Enrollment target
~112 participants
Started
March 2023
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Feng Wang
The First Affiliated Hospital of Zhengzhou University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.